Menu

Search

Search
Enter an event title or description
Select an event type
Select a region
Select a topics

CONGRESS 2023 - Implementation of the Patient Safety Incident Response Framework (PSIRF): an NHS trust perspective

28/09/2023
The presentation gives an overview of the NHS Patient Safety Incident Response Framework, it’s principles and requirements. There is also a brief summary of the Systems Engineering Initiative for Patient Safety (SEIPS) and how this is different to previous models of investigation. The presentation then focusses on how PSIRF has been implemented at Northumbria Healthcare, an acute and community provider in the North East of England, with a focus on the phased implementation approach used by the PSIRF leads. The speaker will also cover the challenges in the implementation to date and the successes experienced so far.

CONGRESS 2023 - In vitro studies of antiviral treatment options for important human pathogens

28/09/2023
This presentation will give delegates an introduction to important human viruses, their treatment with antivirals and possibilities for preventing antiviral resistance. Implications of recently identified metabolic capping of hepatitis C virus.

CONGRESS 2023 - In-house tests to CE marked - Impact on the laboratory (Debate – impact on laboratory vs commercial company)

28/09/2023
The IVDR is the new regulatory instrument for placing IVDs on the European market. The aims of the IVDR are to provide a robust, transparent and sustainable IVD framework, harmonize divergence in implementation (as experienced with the IVDD) and most importantly to increase patient safety. The document runs to 156 pages (compared to 43 for the IVDD, containing 114 articles and 15 annexes. The IVDR places more emphasis on the economic operators (actors) involved in the IVD supply chain, from the manufacturer to the customer.

Manufacturers have the obligations to design and manufacture products in compliance with the IVDR; evaluate product performance and manage risk, have a Quality Management System, create and maintain product technical documentation, conduct post market surveillance, and implement field safety corrective actions. One of the biggest changes with IVDR is the introduction of a new rules-based approach for product classification. Under IVDR, Notified Bodies perform conformity assessment on 80% of IVDs (compared to 20% under the IVDD, which becomes stricter as the risk class increases. There are also enhanced concepts for performance evaluation and clinical evidence.

Under the IVDR there is a requirement to state the clinical purpose in the intended use. Thus, in order to comply with the new regulation, manufacturers must revise all intended purpose statements in product labelling. Further, there is the obligation to gather a large amount of data to evaluate both analytical and clinical performance. Manufacturers are required to continually evaluate performance across the whole product lifecycle through post market surveillance and vigilance, with reports for the highest-risk devices uploaded to the new EUDAMED database on an annual basis.

CONGRESS 2023 - Introduction to the UKAS ISO 15189:2022 transition (Thursday)

28/09/2023
This session provides an overview of the key changes to the ISO 15189 standard and explains the UKAS transition process including deadlines and actions to be taken by accredited organisations.

The same session is being run on Monday, Tuesday and Thursday to ensure as many delegates as possible are able to attend.

CONGRESS 2023 - ISO 15189:2022 Q&A (Thursday)

28/09/2023
ISO 15189:2022 Q&A (Thursday)

CONGRESS 2023 - Lassa fever virus & emerging mammarenaviruses

28/09/2023
The Arenaviridae have the dubious distinction of containing among their members one of greatest proportions of hazard group 4 viruses of any recognised taxonomic family. These viruses cause persistent asymptomatic infections in their rodent reservoirs, however zoonotic spill over often results in viral haemorrhagic fever (VHF) and high mortality. Transmission to humans occurs via contact with infected rodent excreta, through contaminated food and inhalation of aerosols. Human to human transmission also occurs. In sub-Sharan West Africa, Lassa virus (LASV) has been identified as a VHF since 1969 and is endemic over much of rural Nigeria, the countries of Mano River Union, Ghana, Togo and Benin.

From a global health security perspective, it is of significant international interest since it the most commonly imported VHF into non-endemic countries. In nearly every imported circumstance, the cryptic nature of Lassa fever and related difficulties in diagnosis, places enormous demand on clinical, laboratory and public health resources of the recipient country. Given our current understanding of LASV and other evolving members of the genus, attention should be focused on other new and emerging mammarenaviruses which have similar incubation times and could result in similar human disease with a propensity to overburden public health systems.

CONGRESS 2023 - Managing the Human Tissue Authority inspection and selected case studies

28/09/2023
I wish to offer a practical guide to working with the Human Tissue Authority.



I will provide examples of what to do and how to do it when issues arise



I will take you through the paperwork involved

I will describe how best to approach HTA reportable incidents

I will take you through how to prepare for the HTA inspection

This will be a very hands on guide and strongly welcome participation from the audience.

CONGRESS 2023 - Meet the Examiner Session

28/09/2023
Meet the Examiner Session

CONGRESS 2023 - Meet the Microbiology Experts

28/09/2023
Meet the Microbiology Experts

CONGRESS 2023 - National Point-of-Care Strategy

28/09/2023
National Point-of-Care Strategy
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11
  11. ...
  12. 44